New Healthcare market report from Business Monitor International: "Japan Pharmaceuticals & Healthcare Report Q4 2012"
Boston, MA -- (SBWIRE) -- 10/09/2012 -- BMI View: The prospects for Japan's pharmaceutical market over the medium term are very positive. The country has one of the largest pensionable populations, healthcare is readily accessible, the government appreciates investment in biomedical research and the regulatory regime balances the requirements of the major stakeholders. The key downside risk in the world's second-largest pharmaceutical market is a negative macroeconomic adjustment, such as a domestic debt crisis, which would affect public and private spending on medical services. Headline Expenditure Projections ???? Pharmaceuticals: JPY10,157bn (US$127.4bn) in 2011 to JPY10,205bn (US$130.8bn) in 2012; +0.5% in local currency terms and +2.7% in US dollar terms. Our short-term forecast has been revised down slightly from Q212 due to greater awareness about the impact of the April 2012 medicine price cuts. ???? Healthcare: JPY39,824bn (US$499bn) in 2011 to JPY40,096bn (US$514bn) in 2012; +0.7% in local currency terms and +2.9% in US dollar terms. Our forecast has been revised down from Q212 due to macroeconomic factors. ???? Medical Devices: JPY2,220bn (US$27.8bn) in 2011 to JPY2,240bn (US$28.7n) in 2012; +0.9% in local currency terms and +3.2% in US dollar terms. Our forecast has been revised down from Q112 due to macroeconomic factors. Risk/Reward Rating: Japan's Pharmaceutical Risk/Reward Ratings (RRRs) score for Q312, 75.5, is unchanged from Q212, underlining its status as the most attractive market in Asia Pacific. The country scores highly for every major category of the proprietary ratings system. It is only let down by two of the 15 sub-categories, namely market growth and population growth. Key Trends And Developments ???? In March 2012, Asahi Kasei said it will purchase the US medical equipment producer Zoll Medical for US$2.21bn to increase its focus on the global healthcare business and decrease its dependence on its chemicals and fibres operations. Asahi Kasei wants to extend its business footprint in the US.
View Full Report Details and Table of Contents
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Healthcare research reports at Fast Market Research
You may also be interested in these related reports:
- Sweden Pharmaceuticals & Healthcare Report Q4 2012
- Cipher Pharmaceuticals Inc. (DND) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Egypt Pharmaceuticals & Healthcare Report Q4 2012
- Turkey Pharmaceuticals & Healthcare Report Q4 2012
- Netherlands Pharmaceuticals & Healthcare Report Q4 2012
- Galectin Therapeutics, Inc. (GALT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Latvia Pharmaceuticals & Healthcare Report Q4 2012
- Australia Pharmaceuticals & Healthcare Report Q4 2012
- Taiwan Pharmaceuticals & Healthcare Report Q4 2012
- Pharmaceutical & Healthcare Annual Deals Analysis 2012
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)